Results 91 to 100 of about 41,944 (264)

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair

Cancer Biology & Medicine, 2022
Objective: We aimed to investigate the radiosensitizing efficacy of the poly-ADP-ribose polymerase (PARP) inhibitor, olaparib, and the Bloom syndrome protein (BLM) helicase inhibitor, ML216, in non-small cell lung cancer (NSCLC) cells.
Yangyang Kong, Chang Xu, Xiaohui Sun, Hao Sun, Xiaotong Zhao, Ningning He, Kaihua Ji, Qin Wang, Liqing Du, Jinhan Wang, Manman Zhang, Yang Liu, Yan Wang, Qiang Liu   +13 more
doaj   +1 more source

Patient derived xenograft models of small-cell lung cancer provide molecular insights into mechanisms of chemotherapy cross-resistance [PDF]

, 2018
Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a 5% survival rate over 5 years. Though SCLC comprises 13% of all cases of lung cancer the median survival time of 14.5 months has seen little improvement over the last four ...
Myers, David Thomas
core  

Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux.

Pharmacological Research
Sepsis is a dysregulated response to infection that can result in life-threatening organ failure, and septic cardiomyopathy is a serious complication involving ferroptosis.
Ruixue Liu, Fengjuan Li, Shuai Hao, Dongyao Hou, Xue Zeng, He Huang, Gautam Sethi, Jun Guo, Chenyang Duan   +8 more
semanticscholar   +1 more source

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology, 2019
Summary Background Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in ...
J. Mateo, N. Porta, D. Bianchini, U. McGovern, T. Elliott, Robert J. Jones, I. Syndikus, C. Ralph, Suneil Jain, M. Varughese, O. Parikh, S. Crabb, A. Robinson, D. McLaren, A. Birtle, J. Tanguay, S. Miranda, I. Figueiredo, G. Seed, C. Bertan, P. Flohr, Berni Ebbs, P. Rescigno, G. Fowler, A. Ferreira, R. Riisnaes, Rita Pereira, A. Curcean, R. Chandler, M. Clarke, B. Gurel, M. Crespo, Daniel Nava Rodrigues, S. Sandhu, A. Espinasse, P. Chatfield, N. Tunariu, W. Yuan, E. Hall, S. Carreira, J. D. de Bono   +40 more
semanticscholar   +1 more source

Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

International Journal of Gynecological Cancer, 2023
Objective In the PAOLA-1/ENGOT-ov25 trial (NCT02477644), adding maintenance olaparib to bevacizumab provided a substantial progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and homologous recombination deficiency (
Domenica Lorusso, M. Mouret-Reynier, Philip Harter, C. Cropet, C. Caballero, P. Wolfrum-Ristau, Toyomi Satoh, I. Vergote, Gabriella Parma, T. Nøttrup, C. Lebreton, P. Fasching, C. Pisano, L. Manso, Hugues Bourgeois, I. Runnebaum, C. Zamagni, A. Hardy-Bessard, A. Schnelzer, M. Fabbro, B. Schmalfeldt, D. Berton, A. Belau, J. Lotz, M. Gropp-Meier, L. Gladieff, Hans-Joachim Lück, S. Abadie-Lacourtoisie, E. Pujade-Lauraine, I. Ray-Coquard   +29 more
semanticscholar   +1 more source

A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer

Case Reports in Oncological Medicine, 2018
Olaparib was first FDA approved for use in women with advanced ovarian cancer and germline BRCA mutations. Based on the results of subsequent research, the use of this drug has been expanded to patients with metastatic breast cancer with germline BRCA ...
Megan Wheelden, Leah Cream, Jeffrey Sivik, Mark Robson   +3 more
doaj   +1 more source

A ribose-functionalized NAD+ with unexpected high activity and selectivity for protein poly-ADP-ribosylation. [PDF]

, 2019
Nicotinamide adenine dinucleotide (NAD+)-dependent ADP-ribosylation plays important roles in physiology and pathophysiology. It has been challenging to study this key type of enzymatic post-translational modification in particular for protein poly-ADP ...
Chen, Jingwen, Cheng, Qinqin, Dai, Zhefu, Evdokimov, Nikolai M, Lam, Albert T, Louie, Stan G, Lu, Yanran, Pei, Hua, Zhang, Xiao-Nan, Zhang, Yong   +9 more
core   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2^MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors

Cells
Resistance to olaparib is the major obstacle in targeted therapy for ovarian cancer (OC) with poly(ADP-ribose) polymerase inhibitors (PARPis), prompting studies on novel combination therapies to enhance olaparib efficacy.
Łukasz Biegała, Damian Kołat, Arkadiusz Gajek, Elżbieta Płuciennik, Agnieszka Marczak, Agnieszka Śliwińska, Michał Mikula, Aneta Rogalska   +7 more
doaj   +1 more source

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation

Cancer Medicine, 2018
Cholangiocarcinoma (CCA) is a highly malignant tumor with resistance to radiotherapy alone. Olaparib, a highly potent poly(ADP‐ribose) polymerase (PARP) inhibitor, has been shown to sensitize many types of tumor to radiotherapy.
Yize Mao, Xin Huang, Zeyu Shuang, Guohe Lin, Jun Wang, Fangting Duan, Jianlin Chen, Shengping Li   +7 more
doaj   +1 more source